Literature DB >> 10873093

Inducible nitric oxide synthase expression, apoptosis, and angiogenesis in in situ and invasive breast carcinomas.

M Vakkala1, K Kahlos, E Lakari, P Pääkkö, V Kinnula, Y Soini.   

Abstract

In this investigation, we studied the expression of inducible nitric oxide synthase (iNOS) and its association to apoptosis and angiogenesis in 43 in situ and 68 invasive breast carcinomas. Its expression was studied immunohistochemically using a polyclonal iNOS antibody, and the staining was evaluated both in tumor and stromal cells. Apoptosis was detected by 3' end labeling of fragmented DNA (terminal deoxynucleotidyl transferase-mediated nick end labeling method). Vascularization was detected immunohistochemically using an antibody to the FVIII-related antigen, and calculated microvessel densities were determined. In addition to strong iNOS expression in stromal cells, iNOS positivity was observed in tumor cells in 46.5% of in situ and 58.8% of invasive carcinomas. In invasive carcinomas, there were more cases with iNOS positivity both in tumor and stromal cells compared to in situ carcinomas (0.007). The proportion of cases with iNOS-positive tumor cells increased in in situ carcinomas from grade I to III (20.0%, 46.2%, and 73.3%). In invasive ductal carcinomas, there were more cases with iNOS-positive tumor cells than with in situ carcinomas (P = 0.04). Carcinomas with both iNOS-positive tumor and stromal cells had a higher apoptotic index (P = 0.02) and a higher calculated microvessel densities index (P = 0.02). A high number of iNOS-positive stromal cells associated with metastatic disease (P = 0.05). The results show that breast carcinoma cells, in addition to stromal cells, express iNOS and are capable of producing NO. Carcinomas with iNOS-positive tumor and stromal cells have a higher apoptotic indices and increased vascularization, suggesting that iNOS contributes to promotion of apoptosis and angiogenesis in breast carcinoma. The association of the number of iNOS-positive stromal cells with metastatic disease might be attributable to stimulation of angiogenesis, resulting in a higher vascular density and consequently a higher probability for tumor cells to invade.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10873093

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients.

Authors:  Sharon A Glynn; Brenda J Boersma; Tiffany H Dorsey; Ming Yi; Harris G Yfantis; Lisa A Ridnour; Damali N Martin; Christopher H Switzer; Robert S Hudson; David A Wink; Dong H Lee; Robert M Stephens; Stefan Ambs
Journal:  J Clin Invest       Date:  2010-10-18       Impact factor: 14.808

2.  Inducible nitric oxide synthase drives mTOR pathway activation and proliferation of human melanoma by reversible nitrosylation of TSC2.

Authors:  Esther Lopez-Rivera; Padmini Jayaraman; Falguni Parikh; Michael A Davies; Suhendan Ekmekcioglu; Sudeh Izadmehr; Denái R Milton; Jerry E Chipuk; Elizabeth A Grimm; Yeriel Estrada; Julio Aguirre-Ghiso; Andrew G Sikora
Journal:  Cancer Res       Date:  2014-01-07       Impact factor: 12.701

3.  The apoptotic inducible effects of salicylic acid on hepatoma cell line: relationship with nitric oxide signaling.

Authors:  Yahui Liu; Yong Wang; Yue Hu; Shuxiong Ge; Keshi Li; Shuangshuang Wang; Li Li
Journal:  J Cell Commun Signal       Date:  2017-02-09       Impact factor: 5.782

4.  Altered tryptophan metabolism in human meningioma.

Authors:  Noble Kumar Talari; Manas Panigrahi; Sailaja Madigubba; Sundaram Challa; Prakash Babu Phanithi
Journal:  J Neurooncol       Date:  2016-07-29       Impact factor: 4.130

5.  Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy.

Authors:  Andrew G Sikora; Alexander Gelbard; Michael A Davies; Daisuke Sano; Suhendan Ekmekcioglu; John Kwon; Yared Hailemichael; Padmini Jayaraman; Jeffrey N Myers; Elizabeth A Grimm; Willem W Overwijk
Journal:  Clin Cancer Res       Date:  2010-03-09       Impact factor: 12.531

6.  Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells.

Authors:  Ubaldo E Martinez-Outschoorn; Renee M Balliet; Dayana B Rivadeneira; Barbara Chiavarina; Stephanos Pavlides; Chenguang Wang; Diana Whitaker-Menezes; Kristin M Daumer; Zhao Lin; Agnieszka K Witkiewicz; Neal Flomenberg; Anthony Howell; Richard G Pestell; Erik S Knudsen; Federica Sotgia; Michael P Lisanti
Journal:  Cell Cycle       Date:  2010-08-28       Impact factor: 4.534

Review 7.  Environmental immune disruptors, inflammation and cancer risk.

Authors:  Patricia A Thompson; Mahin Khatami; Carolyn J Baglole; Jun Sun; Shelley A Harris; Eun-Yi Moon; Fahd Al-Mulla; Rabeah Al-Temaimi; Dustin G Brown; Annamaria Colacci; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Amedeo Amedei; Roslida A Hamid; Leroy Lowe; Tiziana Guarnieri; William H Bisson
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

8.  Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.

Authors:  Tangying Lu; Rupal Ramakrishnan; Soner Altiok; Je-In Youn; Pingyan Cheng; Esteban Celis; Vladimir Pisarev; Simon Sherman; Michael B Sporn; Dmitry Gabrilovich
Journal:  J Clin Invest       Date:  2011-09-12       Impact factor: 14.808

Review 9.  iNOS: a potential therapeutic target for malignant glioma.

Authors:  A Jahani-Asl; A Bonni
Journal:  Curr Mol Med       Date:  2013-09       Impact factor: 2.222

10.  NPM-ALK up-regulates iNOS expression through a STAT3/microRNA-26a-dependent mechanism.

Authors:  Haifeng Zhu; Deeksha Vishwamitra; Choladda V Curry; Roxsan Manshouri; Lixia Diao; Aarish Khan; Hesham M Amin
Journal:  J Pathol       Date:  2013-03-14       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.